<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884815</url>
  </required_header>
  <id_info>
    <org_study_id>UX701-CL301</org_study_id>
    <secondary_id>2020-005266-34</secondary_id>
    <nct_id>NCT04884815</nct_id>
  </id_info>
  <brief_title>Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Seamless, Adaptive, Safety, Dose-Finding, and Phase 3 Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety of single IV doses of UX701&#xD;
      in patients with Wilson disease, to select the UX701 dose with the best benefit/risk profile&#xD;
      based on the totality of safety and efficacy data and to evaluate the effect of UX701 on&#xD;
      copper regulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, seamless, adaptive Phase 1/2/3&#xD;
      clinical study of UX701 in patients with Wilson disease.&#xD;
&#xD;
      Stage 1 (Phase 1/2) is designed to evaluate the safety and efficacy of 3 dose levels of UX701&#xD;
      to establish initial safety of UX701 and select a safe and efficacious dose for further&#xD;
      evaluation. Stage 2 (Phase 3) is designed to evaluate the safety and efficacy of UX701 using&#xD;
      the dose selected in Stage 1. Stage 3 (long-term follow-up) is designed to evaluate the&#xD;
      long-term safety, efficacy, and clinical benefit of UX701. All participants will be followed&#xD;
      for at least 5 years from the time of UX701 administration.&#xD;
&#xD;
      Participants who receive UX701 will receive prophylactic oral corticosteroids. Participants&#xD;
      who receive placebo will receive placebo oral corticosteroids to maintain the study blind.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">January 2031</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Treatment-Related TEAEs, and Treatment-Related TESAEs</measure>
    <time_frame>Up to Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Change in 24-hour Urinary Copper Concentration from Baseline at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Change in Total Copper from Baseline at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Change in Total Ceruloplasmin from Baseline at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Change in Total Non-Ceruloplasmin-bound Copper (NCC) from Baseline at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Change in Total Free Copper from Baseline at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Change in Total Ceruloplasmin Activity from Baseline at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Percent Reduction in Standard of Care (SOC) Medication by Week 52</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Number of Subjects Who Discontinue SOC Medication by Week 52</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Number of Consecutive Weeks off SOC Medication at Week 52</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Change in 24-hour Urinary Copper Concentration from Baseline at Week 52, evaluated for superiority</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Percent Reduction in SOC Medication by Week 52, Evaluated for Superiority</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Change in Ceruloplasmin Activity Levels from Baseline at Week 52, Evaluated for Superiority</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Change in Wilson Disease Functional Rating Scale (WDFRS) Patient Scores from Baseline at Week 52, Evaluated for Superiority</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Number of Subjects who Discontinue SOC Medication by Week 52</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Change in WDFRS Clinician Scores from Baseline at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Change in Liver Copper Concentration Assessed by Liver Biopsy from Baseline at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Stage 2: Development of Anti-ATP7B Antibodies</measure>
    <time_frame>Up to Week 104</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of TEAEs, TESAEs, Treatment-Related TEAEs, and Treatment-Related TESAEs</measure>
    <time_frame>Up to Week 312</time_frame>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Wilson Disease</condition>
  <arm_group>
    <arm_group_label>Stage 1: UX701 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive a single, peripheral intravenous (IV) infusion of UX701 at dose level 1 plus prophylactic oral corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Placebo for Dose Level 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: UX701 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusion of UX701 at dose level 2 plus prophylactic oral corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Placebo Dose Level 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: UX701 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusion of UX701 at dose level 3 plus prophylactic oral corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Placebo Dose Level 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: UX701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusion of UX701 at a dose selected in Stage 1 plus prophylactic oral corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3: UX701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants originally randomized in Stage 1 or Stage 2 to placebo will be eligible for a single, peripheral IV infusion of UX701 at the selected dose plus prophylactic oral corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants originally randomized in Stage 2 to UX701 will receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>UX701</intervention_name>
    <description>nonreplicating, recombinant gene transfer vector</description>
    <arm_group_label>Stage 1: UX701 Dose Level 1</arm_group_label>
    <arm_group_label>Stage 1: UX701 Dose Level 2</arm_group_label>
    <arm_group_label>Stage 1: UX701 Dose Level 3</arm_group_label>
    <arm_group_label>Stage 2: UX701</arm_group_label>
    <arm_group_label>Stage 3: UX701</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline</description>
    <arm_group_label>Stage 1: Placebo Dose Level 2</arm_group_label>
    <arm_group_label>Stage 1: Placebo Dose Level 3</arm_group_label>
    <arm_group_label>Stage 1: Placebo for Dose Level 1</arm_group_label>
    <arm_group_label>Stage 2: Placebo</arm_group_label>
    <arm_group_label>Stage 3: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral corticosteroids</intervention_name>
    <description>Participants who receive UX701 (at Baseline or during Stage 3) will receive prophylactic oral corticosteroids.</description>
    <arm_group_label>Stage 1: UX701 Dose Level 1</arm_group_label>
    <arm_group_label>Stage 1: UX701 Dose Level 2</arm_group_label>
    <arm_group_label>Stage 1: UX701 Dose Level 3</arm_group_label>
    <arm_group_label>Stage 2: UX701</arm_group_label>
    <arm_group_label>Stage 3: UX701</arm_group_label>
    <other_name>prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for oral corticosteroids</intervention_name>
    <description>Participants who receive placebo investigational product (IP) will receive placebo oral corticosteroids to maintain the study blind.</description>
    <arm_group_label>Stage 1: Placebo Dose Level 2</arm_group_label>
    <arm_group_label>Stage 1: Placebo Dose Level 3</arm_group_label>
    <arm_group_label>Stage 1: Placebo for Dose Level 1</arm_group_label>
    <arm_group_label>Stage 2: Placebo</arm_group_label>
    <arm_group_label>Stage 3: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of Wilson disease&#xD;
&#xD;
          -  Ongoing copper chelator (ie, penicillamine, trientine) and/or zinc therapy for at&#xD;
             least 12 months at screening, with no medication or dose changes for at least 6 months&#xD;
             at screening.&#xD;
&#xD;
          -  Stable Wilson disease as evidenced by stable laboratory values during the Screening&#xD;
             Period&#xD;
&#xD;
          -  Ongoing restriction of high copper containing foods for at least 12 months at&#xD;
             Screening, continued through study participation.&#xD;
&#xD;
          -  Willing and able to comply with all study procedures and requirements, including&#xD;
             frequent blood collection, total urine collection over a 24-hour period,&#xD;
             patient-reported outcome assessments, and long-term follow-up&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Detectable pre-existing antibodies to the AAV9 capsid.&#xD;
&#xD;
          -  Stage 1 only: History of copper chelator or zinc therapy noncompliance, in the&#xD;
             Investigator's judgment, within 12 months prior to Screening.&#xD;
&#xD;
          -  History of liver transplant.&#xD;
&#xD;
          -  Decompensated hepatic cirrhosis or presence of advanced liver disease as evidenced by&#xD;
             portal hypertension, ascites, splenomegaly, esophageal varices, hepatic&#xD;
             encephalopathy, or a liver biopsy with evidence of stage III fibrosis.&#xD;
&#xD;
          -  Significant hepatic inflammation as evidenced by imaging or any of the laboratory&#xD;
             abnormalities.&#xD;
&#xD;
          -  Model for End-Stage Liver Disease (MELD) score &gt; 13.&#xD;
&#xD;
          -  Wilson Index score &gt; 11&#xD;
&#xD;
          -  Hemoglobin &lt; 9 g/dL&#xD;
&#xD;
          -  History of prolonged QT syndrome (QT interval &gt; 450 msec on electrocardiogram [ECG])&#xD;
&#xD;
          -  Presence of Stage 3 or higher chronic kidney disease based on estimated glomerular&#xD;
             filtration rate &lt; 60 mL/min/1.73 m2.&#xD;
&#xD;
          -  Marked neurological deficit or compromise that, in the Investigator's opinion, would&#xD;
             interfere with the subject's safety or ability to participate in the study.&#xD;
&#xD;
          -  Moderate to severe depression, recent or active suicidal ideation with intent or&#xD;
             suicidal behavior, psychosis, or unstable psychiatric illness.&#xD;
&#xD;
          -  Participation in another gene transfer study or use of another gene transfer product&#xD;
             before or during study participation.&#xD;
&#xD;
          -  Subjects with known hypersensitivity to amide-containing local anesthetics are&#xD;
             excluded from participating in the optional liver biopsy substudy.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/ Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ultragenyx Pharmaceutical Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patients Contact: Trial Recruitment</last_name>
    <phone>1-888-756-8657</phone>
    <email>trialrecruitment@ultragenyx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HCPs Contact: Medical Information</last_name>
    <phone>1-888-756-8657</phone>
    <email>medinfo@ultragenyx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatolenticular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the rarity of Wilson Disease, individual patient data will not be shared in order to safeguard patient privacy. The study protocol and statistical analysis plan for this study will be available with the tabulated results once posted.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

